HK Stock Movement | JD HEALTH (06618) Rises Nearly 4% in Early Trading as Flu Season Peaks, Boosting Demand for Test Kits and Pediatric Medications

Stock News12-01

JD HEALTH (06618) surged nearly 4% in early trading, with a 3.19% increase to HK$63 by the time of reporting, recording a turnover of HK$149 million. The rise follows reports of heightened demand for respiratory infection testing amid the ongoing flu season. Data from JD HEALTH shows a significant surge in sales of flu test kits, with multi-test kits emerging as a new trend. To meet demand, JD HEALTH has partnered with brands to implement a supply guarantee mechanism, ensuring stable availability without price hikes. Last month, its medical equipment division formed an IVD brand alliance with multiple companies to forecast demand and optimize inventory. Additionally, JD HEALTH has upgraded delivery efficiency, offering same-hour delivery in select regions.

In another development, JD HEALTH exclusively launched a 15mg×18 sachet course pack of Tamiflu® (oseltamivir) granules, addressing the challenges of dosage mismatch and medication waste in pediatric flu treatment. Designed for a standard 5-day course, this pack caters to children aged 1+ and weighing under 15kg, simplifying medication management for parents. Since its launch, daily sales have grown over 100%, making it a top choice for household flu preparedness.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment